Marlborough-based Advanced Cell Technology (ACT) has finished treating three more patients in its two U.S. clinical trials for embryonic stem cell therapy to reverse macular degeneration and dystrophy, the biotechnology company said.
The second cohort of patient testing for both treatments is now complete, with the fifth and sixth patients participating in ACT’s clinical trial for dry age-related macular degeneration – completing the second cohort of patients – and the sixth patient participating in the company’s clinical trial for Stargardt’s macular Dystrophy. All three patients are recovering, according to a statement by the company.
“We could not be more pleased to have now completed the second, higher-dose patient cohort in both of our U.S. clinical trials,” said Gary Rabin, chairman and CEO of ACT.
The company is now anticipating a third round of clinical trials for the treatments, according to Rabin. A total of three rounds will be conducted in the U.S. and Europe, the company said.
